Results 81 to 90 of about 43,883 (271)
Pulmonary invasive mucinous adenocarcinoma
Histopathology, 2023 Invasive mucinous adenocarcinoma (IMA) is a relatively rare subtype of lung adenocarcinoma, composed of goblet and/or columnar tumour cells containing abundant intracytoplasmic mucin vacuoles. While a majority of IMAs are driven by KRAS mutations, recent studies have identified distinct genomic alterations, such as NRG1 and ERBB2 fusions.
Wei‐Chin Chang +2 more
openaire +2 more sources
Annals of Gastroenterological Surgery, EarlyView.This study aimed to determine whether immuno‐nutritional and inflammatory markers could serve as predictors of the outcomes of postoperative adjuvant chemotherapy for stage III colorectal cancer in elderly patients. Postoperative lymphocyte‐to‐monocyte ratio and postoperative C‐reactive protein‐to‐albumin ratio accurately predicted the efficacy of ...
Tomoya Tago +6 more
wiley +1 more source
Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles
Advanced NanoBiomed Research, EarlyView.This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley +1 more source
Giant mucinous adenocarcinoma of the appendix: a case report
Journal of Medical Case Reports, 2017 Background Appendiceal mucinous adenocarcinoma is an extremely rare disease in clinical practice. Here, we report a case of unprecedented size that occupied the entire abdomen of a man.
Sheng-Chun Dang +9 more
doaj +1 more source
Consumed by Abdominal Distention
Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Mucinous adenocarcinoma of urachus: A tailored approach
, 2016 Vesical adenocarcinomas are uncommon, accounting for less than 2% of all malignant urinary bladder tumors. Of these, urachal adenocarcinoma represents a rare subset.
M. Vijay Kumar +6 more
core +1 more source
Nomogram model for the diagnosis of solitary nodular pulmonary mucinous adenocarcinoma
Scientific ReportsThe objective of this study was to develop a nomogram model based on the natural progression of tumor and other radiological features to discriminate between solitary nodular pulmonary mucinous adenocarcinoma and non-mucinous adenocarcinomas.
Feiyang Zhong +4 more
doaj +1 more source
A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis
Journal of Ovarian Research, 2022 Background Ovarian mucinous carcinoma is a disease that requires unique treatment. But for a long time, guidelines for ovarian serous carcinoma have been used for the treatment of ovarian mucinous carcinoma.
Li Yang +7 more
doaj +1 more source
Chronic Diseases and Translational Medicine, EarlyView.Features the major cell type compositions among colon and liver metastasis. (A) The study design for single‐cell data analysis. (B) The annotated major cell types. Each type was labeled with a special color. (C) Dot plot of canonical marker genes for major cell types. (D) Bar plot of the percentage for each cell type in individuals. (E) Bar plot of the
Zhixun Zhao +10 more
wiley +1 more source